Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat and FOLFOX in Pancreatic Adenocarcinoma
NCT03760614Phase 1Withdrawn
- Sponsor
- Abramson Cancer Center
- Start
- Jan 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of entinostat in pancreatic adenocarcinoma (PDAC), sponsored by Abramson Cancer Center. Primary endpoint: Dose Limiting Toxicity at 28 days. Planned start Jan 2021; status: withdrawn.
02
Drugs
entinostat
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03760614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03760614.